Cambridge Investment Research Advisors, Inc. Biotechnology

Cambridge Investment Research Advisors, Inc.

$32.9 Billion
Q2 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
NVO Novo Nordisk A S	$123B	$14.4 Million 0.04% of portfolio	207,969	Q2 2025 Added 29.39%
VRTX Vertex Pharmaceuticals Inc	$102B	$7.72 Million 0.02% of portfolio	17,329	Q2 2025 Added 6.11%
EXEL Exelixis, Inc.	$12.6B	$3.8 Million 0.01% of portfolio	86,142	Q2 2025 Added 2.44%
CRSP Crispr Therapeutics Ag	$4.36B	$2.21 Million 0.01% of portfolio	45,467	Q2 2025 Added 16.02%
REGN Regeneron Pharmaceuticals, Inc.	$60.9B	$2.05 Million 0.01% of portfolio	3,905	Q2 2025 Reduced 0.38%
BBIO Bridge Bio Pharma, Inc.	$7.8B	$1.82 Million 0.01% of portfolio	42,087	Q2 2025 Added 36.64%
ARGX Argenx Se	$42.2B	$1.77 Million 0.01% of portfolio	3,214	Q2 2025 Added 226.29%
SBTX Silverback Therapeutics, Inc.	$0	$1.52 Million 0.0% of portfolio	87,162	Q2 2025 Added 0.0%
CORT Corcept Therapeutics Inc	$7.96B	$754,000 0.0% of portfolio	10,272	Q2 2025 Reduced 14.44%
CRBU Caribou Biosciences, Inc.	$116M	$736,000 0.0% of portfolio	584,446	Q2 2025 Reduced 4.57%
TARS Tarsus Pharmaceuticals, Inc.	$1.38B	$703,000 0.0% of portfolio	17,350	Q2 2025 Reduced 25.05%
BGNE Bei Gene, Ltd.	$23.5B	$681,000 0.0% of portfolio	2,815	Q2 2025 New
SMMT Summit Therapeutics Inc.	$3.69B	$656,000 0.0% of portfolio	30,820	Q2 2025 New
RXRX Recursion Pharmaceuticals, Inc.	$875M	$644,000 0.0% of portfolio	127,249	Q2 2025 Added 8.65%
UTHR United Therapeutics Corp	$18.4B	$543,000 0.0% of portfolio	1,891	Q2 2025 Reduced 79.4%
MRNA Moderna, Inc.	$9.93B	$526,000 0.0% of portfolio	19,056	Q2 2025 Reduced 8.74%
ALNY Alnylam Pharmaceuticals, Inc.	$57.6B	$451,000 0.0% of portfolio	1,384	Q2 2025 Added 75.41%
BNTX Bio N Tech Se	$25.3B	$451,000 0.0% of portfolio	4,237	Q2 2025 Reduced 2.53%
KYMR Kymera Therapeutics, Inc.	$2.53B	$394,000 0.0% of portfolio	9,025	Q2 2025 Added 0.12%
EDIT Editas Medicine, Inc.	$186M	$389,000 0.0% of portfolio	176,604	Q2 2025 Added 106.03%
VRNA Verona Pharma PLC	$6.49B	$382,000 0.0% of portfolio	4,042	Q2 2025 Reduced 34.47%
MDGL Madrigal Pharmaceuticals, Inc.	$7.52B	$375,000 0.0% of portfolio	1,238	Q2 2025 Added 7.84%
HALO Halozyme Therapeutics, Inc.	$10.8B	$365,000 0.0% of portfolio	7,007	Q2 2025 Added 1.91%
VKTX Viking Therapeutics, Inc.	$1.97B	$359,000 0.0% of portfolio	13,566	Q2 2025 Reduced 54.36%
GANX Gain Therapeutics, Inc.	$20.2M	$323,000 0.0% of portfolio	179,500	Q2 2025 Added 201.68%
GALT Galectin Therapeutics Inc	$304M	$256,000 0.0% of portfolio	121,315	Q2 2025 Added 2.3%
SAGE Sage Therapeutics, Inc.	$516M	$250,000 0.0% of portfolio	27,432	Q1 2025 Reduced 1.44%
GERN Geron Corp	$499M	$238,000 0.0% of portfolio	169,025	Q2 2025 Added 3.07%
PGEN Precigen, Inc.	$862M	$236,000 0.0% of portfolio	166,229	Q2 2025 Reduced 13.3%
LQDA Liquidia Corp	$1.74B	$231,000 0.0% of portfolio	18,547	Q2 2025 New
IONS Ionis Pharmaceuticals Inc	$9.09B	$224,000 0.0% of portfolio	5,682	Q2 2025 Reduced 16.49%
OCUL Ocular Therapeutix, Inc	$983M	$224,000 0.0% of portfolio	24,100	Q2 2025 New
NTLA Intellia Therapeutics, Inc.	$868M	$217,000 0.0% of portfolio	23,172	Q2 2025 Added 17.47%
CPRX Catalyst Pharmaceuticals, Inc.	$2.08B	$209,000 0.0% of portfolio	9,615	Q2 2025 Reduced 51.85%
AVXL Anavex Life Sciences Corp.	$747M	$184,000 0.0% of portfolio	20,003	Q2 2025 Reduced 91.94%
ROIV Roivant Sciences Ltd.	$10.2B	$179,000 0.0% of portfolio	15,900	Q2 2025 Reduced 65.46%
PRTA Prothena Corp Public LTD CO	$396M	$166,000 0.0% of portfolio	27,311	Q2 2025 Added 168.7%
XERS Xeris Biopharma Holdings, Inc.	$1.04B	$162,000 0.0% of portfolio	34,642	Q2 2025 Added 0.29%
MNKD Mannkind Corp	$1.39B	$144,000 0.0% of portfolio	38,522	Q2 2025 Reduced 21.79%
CSBR Champions Oncology, Inc.	$86.5M	$90,000 0.0% of portfolio	12,252	Q1 2024 New
IOVA Iovance Biotherapeutics, Inc.	$382M	$81,000 0.0% of portfolio	46,949	Q2 2025 Added 2.34%
QSI Quantum Si Inc	$143M	$76,000 0.0% of portfolio	38,867	Q4 2024 Reduced 19.4%
INMB Inmune Bio, Inc.	$32.1M	$75,000 0.0% of portfolio	32,575	Q2 2025 Added 41.17%
ALT Altimmune, Inc.	$181M	$72,000 0.0% of portfolio	18,668	Q2 2025 Added 19.15%
MDXG Mimedx Group, Inc.	$811M	$70,000 0.0% of portfolio	11,380	Q2 2025 Reduced 9.9%
HUMA Humacyte, Inc.	$155M	$60,000 0.0% of portfolio	28,796	Q2 2025 Added 105.83%
SLN Silence Therapeutics PLC	$175M	$59,000 0.0% of portfolio	10,194	Q2 2025 New
HRTX Heron Therapeutics, Inc.	$152M	$58,000 0.0% of portfolio	27,967	Q2 2025 Added 0.36%
IBRX Immunity Bio, Inc.	$1.04B	$55,000 0.0% of portfolio	20,950	Q2 2025 Added 16.71%
TSHA Taysha Gene Therapies, Inc.	$159M	$55,000 0.0% of portfolio	23,690	Q2 2025 Added 0.85%

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Investment Research Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Investment Research Advisors, Inc. with notifications on news.